Innovent Biologics, Inc. (1801.HK) HKSE
76.55
-2.3(-2.92%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Innovent Biologics, Inc.
Address
168 Dongping Street
Suzhou, 215123
China
Phone
86 512 6956 6088
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5659
First IPO Date
October 31, 2018
Key Executives
| Name | Title | Pay | Year Born |
| De-Chao Yu | Co-Founder, Chairman & Chief Executive Officer | 49.52M | 1964 |
| Qian Zhang | Chief Commercial Officer, General Manager & Executive Director | 4.89M | 1987 |
| Hao Xi Ede | Executive Director & Fund Managing Partner | 8.09M | 1959 |
| Hui Zhou | Chief R&D Officer for Oncology | 0 | N/A |
| Min Liu | Chief Commercial Officer | 0 | 1973 |
| Cong Ding | General Counsel | 0 | N/A |
| Fei You | Chief Financial Officer | 0 | 1979 |
| Zhengwei Song | Director of IR & Financial Strategy | 0 | N/A |
| Kaisong Zhou | Chief Operating Officer | 0 | N/A |
| Raj Dhodda | Senior Vice President | 0 | N/A |
| Blake Salisbury | Senior Vice President | 0 | N/A |
| Samuel Suhua Zhang | Global Chief Business Officer | 0 | 1968 |
Description
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
